Biotech Trends – From T Cells To GLP-1

Establishing a clear signal in the rapidly evolving biotech landscape requires a keen eye for both groundbreaking technology and fundamental biological insights. In this episode of the Few and Far Between Podcast, Professor Justin Stebbing explores the intersection of artificial intelligence and drug discovery, illustrating how AI can significantly boost productivity and refine the search for existing therapeutic candidates. While the technology excels at designing synthetic proteins and predicting molecular interactions, the ultimate validation remains rooted in rigorous human-centric clinical trials.

The conversation also highlights the emergence of the GLP-1 revolution, as well as how the exploration of regulatory T cells underscores the way deep biological understanding continues to drive the next wave of medical breakthroughs. As the industry shifts, with a notable increase in clinical trial activity originating from China, the focus remains on leveraging global innovation to deliver safer, more effective treatments to patients. Listeners will gain a clear-eyed perspective on which trends are truly transformative and which may not yet live up to the surrounding hype.